Literature DB >> 24717578

Role of epigenetics in pulmonary hypertension.

Tara V Saco1, Prasanna Tamarapu Parthasarathy1, Young Cho1, Richard F Lockey1, Narasaiah Kolliputi2.   

Abstract

A significant amount of research has been conducted to examine the pathologic processes and epigenetic mechanisms contributing to peripheral hypertension. However, few studies have been carried out to understand the vascular remodeling behind pulmonary hypertension (PH), including peripheral artery muscularization, medial hypertrophy and neointima formation in proximal arteries, and plexiform lesion formation. Similarly, research examining some of the epigenetic principles that may contribute to this vascular remodeling, such as DNA methylation and histone modification, is minimal. The understanding of these principles may be the key to developing new and more effective treatments for PH. The purpose of this review is to summarize epigenetic research conducted in the field of hypertension that could possibly be used to understand the epigenetics of PH. Possible future therapies that could be pursued using information from these studies include selective histone deacetylase inhibitors and targeted DNA methyltransferases. Both of these could potentially be used to silence proproliferative or antiapoptotic genes that lead to decreased smooth muscle cell proliferation. Epigenetics may provide a glimmer of hope for the eventual improved treatment of this highly morbid and debilitating disease.
Copyright © 2014 the American Physiological Society.

Entities:  

Keywords:  DNA methylation; histone modification

Mesh:

Substances:

Year:  2014        PMID: 24717578      PMCID: PMC4060002          DOI: 10.1152/ajpcell.00314.2013

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  43 in total

1.  Statement from the National High Blood Pressure Education Program: prevalence of hypertension.

Authors:  M Wolz; J Cutler; E J Roccella; F Rohde; T Thom; V Burt
Journal:  Am J Hypertens       Date:  2000-01       Impact factor: 2.689

2.  Butyrate, an HDAC inhibitor, stimulates interplay between different posttranslational modifications of histone H3 and differently alters G1-specific cell cycle proteins in vascular smooth muscle cells.

Authors:  Omana P Mathew; Kasturi Ranganna; Frank M Yatsu
Journal:  Biomed Pharmacother       Date:  2010-12       Impact factor: 6.529

Review 3.  Epigenetic regulation of vascular smooth muscle cell function in atherosclerosis.

Authors:  Hannes M Findeisen; Florian K Kahles; Dennis Bruemmer
Journal:  Curr Atheroscler Rep       Date:  2013-04       Impact factor: 5.113

Review 4.  Epigenetics and hypertension.

Authors:  Richard M Millis
Journal:  Curr Hypertens Rep       Date:  2011-02       Impact factor: 5.369

5.  Local hypomethylation in atherosclerosis found in rabbit ec-sod gene.

Authors:  M O Laukkanen; S Mannermaa; M O Hiltunen; S Aittomäki; K Airenne; J Jänne; S Ylä-Herttuala
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-09       Impact factor: 8.311

6.  Pulmonary arteriopathy and idiopathic pulmonary arterial hypertension in six dogs.

Authors:  T S Zabka; F E Campbell; D W Wilson
Journal:  Vet Pathol       Date:  2006-07       Impact factor: 2.221

7.  DNA hypomethylation and methyltransferase expression in atherosclerotic lesions.

Authors:  Mikko O Hiltunen; Mikko P Turunen; Tomi P Häkkinen; Juha Rutanen; Maria Hedman; Kimmo Mäkinen; Anna-Mari Turunen; Katriina Aalto-Setälä; Seppo Ylä-Herttuala
Journal:  Vasc Med       Date:  2002-02       Impact factor: 3.239

8.  Epigenetic mechanisms of pulmonary hypertension.

Authors:  Gene H Kim; John J Ryan; Glenn Marsboom; Stephen L Archer
Journal:  Pulm Circ       Date:  2011 Jul-Sep       Impact factor: 3.017

9.  Development of pulmonary arterial hypertension in mice over-expressing S100A4/Mts1 is specific to females.

Authors:  Yvonne Dempsie; Margaret Nilsen; Kevin White; Kirsty M Mair; Lynn Loughlin; Noona Ambartsumian; Marlene Rabinovitch; Margaret R Maclean
Journal:  Respir Res       Date:  2011-12-20

10.  An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension.

Authors:  Jongmin Kim; Yujung Kang; Yoko Kojima; Janet K Lighthouse; Xiaoyue Hu; Micheala A Aldred; Danielle L McLean; Hyekyung Park; Suzy A Comhair; Daniel M Greif; Serpil C Erzurum; Hyung J Chun
Journal:  Nat Med       Date:  2012-12-23       Impact factor: 53.440

View more
  15 in total

Review 1.  Peripheral Arterial Disease Genetics: Progress to Date and Challenges Ahead.

Authors:  Nathan Belkin; Scott M Damrauer
Journal:  Curr Cardiol Rep       Date:  2017-11-01       Impact factor: 2.931

2.  Epigenetic regulation of L-type voltage-gated Ca2+ channels in mesenteric arteries of aging hypertensive rats.

Authors:  Jingwen Liao; Yanyan Zhang; Fang Ye; Lin Zhang; Yu Chen; Fanxing Zeng; Lijun Shi
Journal:  Hypertens Res       Date:  2016-11-24       Impact factor: 3.872

3.  Histone deacetylation contributes to low extracellular superoxide dismutase expression in human idiopathic pulmonary arterial hypertension.

Authors:  Eva Nozik-Grayck; Crystal Woods; Robert S Stearman; Sujatha Venkataraman; Bradley S Ferguson; Kalin Swain; Russell P Bowler; Mark W Geraci; Kaori Ihida-Stansbury; Kurt R Stenmark; Timothy A McKinsey; Frederick E Domann
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-05-27       Impact factor: 5.464

Review 4.  Epigenetics of Mucus Hypersecretion in Chronic Respiratory Diseases.

Authors:  Tara V Saco; Mason T Breitzig; Richard F Lockey; Narasaiah Kolliputi
Journal:  Am J Respir Cell Mol Biol       Date:  2018-03       Impact factor: 6.914

Review 5.  Epigenetic targets for novel therapies of lung diseases.

Authors:  Brian S Comer; Mariam Ba; Cherie A Singer; William T Gerthoffer
Journal:  Pharmacol Ther       Date:  2014-11-15       Impact factor: 12.310

6.  Progress in the understanding and management of pulmonary arterial hypertension.

Authors:  A M Chakrabarti; J A Mitchell; S J Wort
Journal:  Glob Cardiol Sci Pract       Date:  2015-04-04

7.  Differentially methylated regions in patients with rheumatic heart disease and secondary pulmonary arterial hypertension.

Authors:  Dawei Zheng; Xiaoying Chen; Ni Li; Lebo Sun; Qingyun Zhou; Huoshun Shi; Guodong Xu; Jing Liu; Limin Xu; Shiwei Duan; Guofeng Shao
Journal:  Exp Ther Med       Date:  2017-06-22       Impact factor: 2.447

Review 8.  Hallmarks of Pulmonary Hypertension: Mesenchymal and Inflammatory Cell Metabolic Reprogramming.

Authors:  Angelo D'Alessandro; Karim C El Kasmi; Lydie Plecitá-Hlavatá; Petr Ježek; Min Li; Hui Zhang; Sachin A Gupte; Kurt R Stenmark
Journal:  Antioxid Redox Signal       Date:  2017-08-14       Impact factor: 8.401

9.  Epigenetics, inflammation and metabolism in right heart failure associated with pulmonary hypertension.

Authors:  Nolwenn Samson; Roxane Paulin
Journal:  Pulm Circ       Date:  2017-06-19       Impact factor: 3.017

Review 10.  Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension.

Authors:  Jun-Dae Kim; Aram Lee; Jihea Choi; Youngsook Park; Hyesoo Kang; Woochul Chang; Myeong-Sok Lee; Jongmin Kim
Journal:  Exp Mol Med       Date:  2015-07-31       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.